Published: 17 October 2023
Author(s): Janis Timsans, Jenni Emilia Kauppi, Anne Mirjam Kerola, Tiina Maarit Lehto, Hannu Juhani Kautiainen, Markku Jaakko Kauppi
Issue: March 2024
Section: Original article

Elevated serum uric acid (SUA) level, i.e., hyperuricaemia, is independently associated with all-cause mortality as well as with several cause-specific types of mortality [1–9]. It has been reasonably speculated that treating asymptomatic hyperuricaemia (elevated SUA without a history of gout attacks) could be beneficial in reducing mortality. However, current guidelines do not generally recommend treatment of asymptomatic hyperuricaemia since there is a lack of sufficient data supporting a favourable benefit-to-risk ratio of treating hyperuricaemia [10–12].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.